Search
Merck Sharp & Dohme: Keytruda, Lenvatinib, and TACE Gain Approval for New Indication in China
3 week ago /
Read about 0 minute
Author：小编
Merck Sharp & Dohme has announced that its PD-1 inhibitor, Keytruda, in conjunction with Lenvatinib and Transarterial Chemoembolization (TACE) therapy, has been approved for the treatment of unresectable, non-metastatic hepatocellular carcinoma in China. This approval is grounded in the findings of the Phase III clinical trial, LEAP-012.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
